eConsent for Autoimmune Device Studies: What to Get Right
Direct answer
Medical device companies running autoimmune studies should choose eConsent that clearly explains procedure and device risks, shows how the study interacts with existing biologic or DMARD treatment, supports remote and in-clinic signing, and tracks reconsent across long follow-up. Audit-ready records matter because IDE studies face both FDA and IRB oversight.
Why are autoimmune device studies growing?
Device-based therapies are entering immunology. In July 2025, FDA approved the SetPoint System, an implanted vagus nerve stimulator for adults with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to biologic or targeted synthetic DMARDs. Approval was supported by the randomized, sham-controlled RESET-RA trial of 242 patients, and 24-month data were presented at ACR Convergence 2026.
That approval signals more device studies in RA, lupus, inflammatory bowel disease, and psoriasis, from implants and neuromodulation to wearables, injection devices, and home phototherapy. Each brings a consent conversation that is different from a typical drug trial.
What rules shape consent in device studies?
IDE requirements
Device clinical studies follow 21 CFR 812, while 21 CFR 50 sets the general elements of informed consent.
Risk level
Significant risk device studies need both FDA and IRB approval before they start, while nonsignificant risk studies need IRB approval only. Either way, informed consent is required.
Consent elements
Part 50 lists the basic elements every consent must cover, including risks, benefits, alternatives, and confidentiality.
Electronic consent
FDA's eConsent guidance covers how electronic systems can deliver information, check understanding, and capture signatures.
What makes autoimmune device consent harder?
Procedure risks
Implants involve surgery, anesthesia, infection risk, and possible removal. Participants need plain-language explanations, and short videos or diagrams can help.
Interaction with current treatment
People with RA or lupus often take biologics, JAK inhibitors, or steroids. Consent must explain whether they can continue those medicines, what washouts apply, and how flares will be managed.
Sham control and blinding
Sham-controlled device trials ask participants to accept that their device may be inactive for a period. That needs careful, comprehensible wording.
Long follow-up
Implanted devices may be followed for years, so protocol amendments, new safety information, and extension phases lead to reconsent.
Device data
Many devices log usage or sensor data. Participants should understand what is collected, who sees it, and how it is used.
Fatigue and joint pain
Autoimmune symptoms can make long sessions and small touchscreens tiring. Breaks, saved progress, and accessible design help.
What should device teams look for in eConsent?
Multimedia and comprehension checks
Videos, diagrams, and quiz questions that confirm understanding of procedure and sham-control concepts.
Remote and in-clinic signing
Participants often travel to specialty centers, so remote review before the visit reduces burden.
Version control and reconsent alerts
Automatic prompts when a new consent version applies, with records of who signed which version.
Optional consents
Separate choices for future research, device data reuse, or photos, recorded clearly.
Audit trails
Part 11 compliant signatures and complete audit trails for FDA and IRB review.
Connection to study data
Consent status that flows to EDC so no procedure happens before consent is complete.
Comparing eConsent platforms for autoimmune device studies
| Vendor | Known for | Fit for medical device and autoimmune studies |
|---|---|---|
| Curebase | Structured eConsent, eCOA, and EDC on one data model | A strong fit for device companies that want procedure education, remote signing, reconsent tracking, and flare and symptom diaries in one connected record |
| Medidata | Medidata Consent with onsite and remote consent, multimedia, and Rave EDC integration | A fit for device companies already running on Rave |
| Veeva | SiteVault eConsent, free to sites, with remote signing through MyVeeva for Patients | A fit when sites already use SiteVault |
| Medable | Standalone eConsent in 120+ locales with template management and version control | A fit for decentralized or global device programs |
| Advarra | Site-facing eConsent that notifies staff when reconsent is required | A fit for site networks managing long follow-up |
What should device companies ask eConsent vendors?
- Can we add procedure videos and comprehension checks without custom development?
- How are reconsent prompts triggered and tracked over multi-year follow-up?
- Can participants review remotely and sign in clinic, or sign fully remotely?
- How are optional consents for device data and future research recorded?
- Does consent status block study procedures in EDC until complete?
- What documentation supports FDA and IRB inspections?
Where does Curebase fit for autoimmune device studies?
Curebase eConsent shares a platform with Curebase eCOA and EDC. For a device company running an RA or lupus study, consent versions, reconsent history, patient-reported flare and symptom data, and visit data live in one record. Remote and in-clinic signing support participants who travel to specialty centers, and Curebase's team helps sites and participants get started.
Frequently asked questions
Do medical device studies need informed consent?
Yes. Device studies follow 21 CFR 812 and the informed consent requirements of 21 CFR 50, whether they are significant risk or nonsignificant risk studies.
Can eConsent be used in IDE studies?
Yes. FDA guidance describes how electronic systems can present information, assess understanding, and capture signatures, as long as records meet Part 11 expectations.
What should consent explain in an autoimmune device trial?
It should explain procedure and device risks, sham control if used, how current biologic or DMARD treatment is handled, follow-up length, and what device data is collected.
How does eConsent help with long-term device follow-up?
It tracks consent versions, prompts reconsent when new information or amendments apply, and keeps a full history for each participant across years of follow-up.
Is there an FDA-approved device for rheumatoid arthritis?
Yes. FDA approved the SetPoint System, an implanted vagus nerve stimulator, in July 2025 for adults with moderate to severe RA who did not respond to or tolerate advanced therapies.
Does Curebase offer eConsent for medical device studies?
Yes. Curebase eConsent connects with Curebase eCOA and EDC, so device companies can manage consent, reconsent, and patient data in one platform.
